**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 72222

**Manuscript Type:** CASE REPORT

**Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature**

ZhangZ *et al*. Diffuse invasive signet ring cell carcinoma

Zhi Zhang, Peng-Fei Yu, Guo-Li Gu, Yu-Hui Zhang, Yu-Ming Wang, Zhi-Wei Dong, Hai-Rui Yang

**Zhi Zhang, Peng-Fei Yu, Guo-Li Gu, Yu-Hui Zhang, Zhi-Wei Dong, Hai-Rui Yang,** Department of General Surgery, Air Force Medical Center, Chinese People's Liberation Army, Beijing 100142, China

**Yu-Hui Zhang,** Graduate School, Hebei North University, Zhangjiakou 075000, Hebei Province, China

**Yu-Ming Wang,** Health Team, 93656 Troop of Chinese People's Liberation Army, Beijing 101113, China

**Author contributions:** Gu GL, Zhang Z and Yu PF contributed equally to this study; Gu GL designed the research; Zhang Z, Yu PF, Wang YM, Zhang YH, Dong ZW and Yang HR collected and analyzed the clinical data; Gu GL and Zhang Z wrote the manuscript; Gu GL revised the manuscript; all authors issued final approval for the version to be submitted.

**Supported by** Beijing Capital Medical Development Research Fund, No. Shoufa2020-2-5122.

**Corresponding author: Guo-Li Gu, FRCS (Gen Surg), Chief Doctor,** Department of General Surgery, Air Force Medical Center, Chinese People's Liberation Army, No. 30 Fucheng Road, Haidian District, Beijing 100142, China. kzggl@163.com

**Received:** October 15, 2021

**Revised:** December 5, 2021

**Accepted:** December 28, 2021

**Published online:** February 16, 2022

**Abstract**

BACKGROUND

Diffuse invasive signet ring cell carcinoma of the colorectum is extremely rare clinically. This type of colorectal cancer has certain clinical, pathological and biological characteristics that are different from ordinary colorectal cancer.

CASE SUMMARY

A 31-year-old young woman was admitted to the hospital for nearly 1 wk due to recurrent symptoms of mucopurulent bloody stools and abdominal distension. Preoperative colonoscopy showed a ring-shaped intestinal wall mass 10 cm from the rectum to the anus. Three pieces of tumor tissue were removed for examination. The pathological results showed rectal mucinous adenocarcinoma. The patient underwent laparoscopic exploration under general anesthesia, and then laparoscopic total colorectal resection, ileal pouch–anal anastomosis and ileostomy were performed. The patient was switched to a FOLFOX + cetuximab regimen. After the fifth cycle, the patient was unable to tolerate further treatment due to tumor progression and multiple organ dysfunction, and died at the end of May 2020. Overall survival was 7 mo.

CONCLUSION

Carcinogenesis of ulcerative colitis is different from sporadic colon cancer, and the overall prognosis is extremely poor.

**Key Words:** Ulcerative colitis; Colorectal cancer; Signet ring cell carcinoma; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang Z, Yu PF, Gu GL, Zhang YH, Wang YM, Dong ZW, Yang HR. Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature. *World J Clin Cases* 2022; 10(5): 1729-1737

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i5/1729.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i5.1729

**Core tip:** Primary signet-ring cell carcinoma (SRCC) of the colorectum is extremely rare clinically. This type of colorectal cancer has certain clinical, pathological and biological characteristics that are different from ordinary colorectal cancer. We report a rare case of ulcerative colitis leading to diffuse infiltrating SRCC of the colorectum, and review the relevant literature studying the disease.

**INTRODUCTION**

Ulcerative colitis (UC) is a chronic nonspecific disease that is immune mediated and has multiple causes[1]. The disease was previously thought to be prevalent in western countries, with a prevalence of about 79–268/105 per year[2]; however, the number of cases reported in China has gradually increased in recent years, and it has become a more common gastrointestinal disease. The inflammation of the disease occurs mostly in the colonic mucosa and submucosa, usually involving the rectum first, then spreading to the entire colon. Typical clinical manifestations of the disease include mucopurulent bloody stools, abdominal pain, and diarrhea*.* A retrospective analysis of a large sample of cases of UC in China in 2007 found that extraintestinal manifestations were rare, causing only 0.4% of cases of colon cancer[3], and about 15% of patients with UC required colectomy[4]. In this paper, we report a rare case of UC leading to diffuse infiltrating signet ring cell carcinoma (SRCC) of the colorectum, and review the relevant literature.

**CASE PRESENTATION**

***Chief complaints***

A 31-year-old young woman presented with bloody stools.

***History of present illness***

The patient was admitted to the hospital for nearly 1 wk due to recurrent symptoms of mucopurulent bloody stools and abdominal distension.

***History of past illness***

The patient presented to the local hospital 8 years ago with symptoms of mucopurulent bloody stools and abdominal distension. After colonoscopy, she was diagnosed with UC. After taking prednisone acetate tablets orally for > 1 mo and sulfasalazine enteric coated tablets orally for about 1 year according to the doctor’s advice, the symptom of bloody stools was largely controlled, and no review or further treatment was performed.

***Personal and family history***

The patient had no specific history of genetic diseases.

***Physical examination***

The whole abdomen had mild tenderness and no rebound pain. Digital rectal examination: No obvious mass was palpable on the fingertips, and the fingertips were stained with blood.

***Laboratory examinations***

Tumor markers: carcinoembryonic antigen: 16.03 ng/mL↑, cancer antigen 72-4: 17.94 U/mL↑. The patient underwent genetic testing before surgery (gene capture hybridization combined with high-throughput sequencing technology). Reference genome: GRCH37/hg19. The number of target genes exceeded 20000. The results are shown in Tables 1 and 2. A test found that the patient’s tumor mutational burden (TMB) was 26.2/Mb. A high TMB type that suggested that the patient was more likely to benefit from PD-1 antibody monotherapy.

***Imaging examinations***

Preoperative colonoscopy: A ring-shaped intestinal wall mass was seen 10 cm from the rectum to the anus (Figure 1). Three pieces of tumor tissue were removed for examination. The pathological results showed rectal mucinous adenocarcinoma.

Preoperative computed tomography (CT): There were no obvious abnormalities in the scan of the chest and upper and lower abdomen. The enhanced CT scan of the pelvis showed that the rectal wall thickened uniformly in stages, visibly strengthened mucosal layer, blurred fat spaces around the intestines, and a small amount of effusion (Figure 2).

**FINAL DIAGNOSIS**

Rectal cancer caused by UC.

**TREATMENT**

After discussion by the multidisciplinary team for gastrointestinal tumors in our hospital, the patient underwent laparoscopic exploration under general anesthesia on December 2, 2019. During the operation, there was inflammatory exudative ascites in the abdominal and pelvic cavity, obvious inflammatory hyperplasia and edema throughout the entire sigmoid colon and rectum, cancerous umbilical changes at the peritoneal reflection in the middle of the rectum, and obvious dilation and edema of part of the bowel. Scattered small patchy changes could be seen on the surface of the mesentery (Figure 3). Tissue was taken from the peritoneal reflex and sent for pathological examination, which showed SRCC. Laparoscopic total colorectal resection, ileal pouch–anal anastomosis (IPAA) and ileostomy were performed.

Postoperative pathological examination: The rectum and entire colon showed diffuse invasive SRCC. Rectal tumors invaded the submesangial adipose tissue, and colon tumors were confined to the mucosa and submucosa. Intravascular tumor thrombus and nerve invasion could be seen. The full thickness of the appendix showed SRCC, with visible metastasis to lymph nodes around the bowel (36/37) (Figure 4). The pathological stage was IVB (T**4**N**2b**M**1c**).

The patient started XELOX chemotherapy on the day 23 after surgery (oxaliplatin: Intravenous infusion for 3 h, day 1; capecitabine: Oral, 2 times/d, days 1-14). The first cycle of chemotherapy ended on January 7, 2020. Follow-up treatment was carried out at the local hospital.

**OUTCOME AND FOLLOW-UP**

Due to the impact of the COVID-19, the time for patients to receive follow-up chemotherapy was delayed by about 6 wk. After the end of the third cycle of chemotherapy, the patient was examined by imaging, the effects were evaluated as progressive disease, and the patient was switched to a FOLFOX + cetuximab regimen. After the fifth cycle, the patient was unable to tolerate further treatment due to tumor progression and multiple organ dysfunction, and died at the end of May 2020. Overall survival was 7 mo.

**DISCUSSION**

SRCC is a rare histological subtype of adenocarcinoma[5] that contains abundant intracytoplasmic mucin that displaces the nuclei to the periphery, thereby giving the characteristic appearance of an SRC[6]. Primary SRCC of the colon is extremely rare[7]. A study in the 20th century[8] found that only 11 cases of primary SRCC of the colon were found out of 12000 cases of primary colon cancer, with an incidence rate < 1/1000 cases of common colorectal adenocarcinoma. In about 80% of cases[9], the lesions are seen in the left colon at the distal end of the splenic flexure. This rare colorectal cancer has certain clinical, pathological and biological characteristics that are different from those of ordinary colorectal cancer, and which can be recognized as a stage-independent prognostic factor for adverse outcomes in colorectal cancer[10]. Following Laufman and Saphir[11] who first reported SRCC that occurred in the colon in 1951, new cases have been continuously reported[12-16]. Most cases are basically similar in general type, consisting of invasive tumors involving the entire thickness of the colon or rectal wall, leading to obvious thickening and induration. The lesions generally infiltrate the entire cecal wall and involve the proximal part of the appendix. Due to the infiltrative growth and highly aggressive nature of the tumor, most patients are found at an advanced stage, and the overall prognosis is extremely poor[13]. The difference between this patient and previous cases is that she had a clear history of UC, protracted course of disease and irregular follow-up treatment, providing a suitable environment for the later occurrence and development of tumors. Pontes *et al*[17] also reported a similar case to the present one: That patient had a 9-year history of UC, and although undergoing close endoscopic examination and treatment, he was eventually diagnosed with cancer. The pathological examination of the excised specimen showed SRCC of the sigmoid colon. Current research suggests that the occurrence of carcinoma in UC is positively correlated with the duration, degree of inflammation and extent of involvement of the patient[18]; and its occurrence and development experience the process of inflammation-low-grade intraepithelial neoplasia to high-grade intraepithelial neoplasia-carcinogenesis[19], which is different from the mode of gene mutation adenoma canceration of sporadic colorectal cancer[20]. In the same way, the mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) in this patient were all positive and microsatellite stable, and no mutations closely related to colorectal cancer were detected by genetic testing, yet advanced bowel cancer was detected at such a young age. In addition to the rarity of the case itself, it was more related to the history of UC.

As mentioned earlier, UC is a major type of inflammatory bowel disease (IBD). In the past two decades, the overall incidence of UC in China has been increasing year by year[3], but a consensus has not yet been reached on the exact pathogenesis. It is now believed that a combination of genetic, environmental, intestinal flora and host immune system factors contribute to the development of the disease[21-24]. Studies have shown[25,26] that 8%-14% of patients with UC have a family history of IBD, and the risk of first-degree relatives suffering from the disease is four times higher than that of the general population. To date, genome-wide association studies have confirmed the presence of nearly 200 disease risk genes for IBD; most of which can cause both UC and Crohn’s disease[27,28]. At present, research on IBD susceptibility genes is mainly focused on Crohn’s disease, and the internal molecular mechanism of the pathogenesis of UC has not been fully elucidated[29]. Compared with Crohn’s disease, UC has a weaker correlation with disease inheritance. Mantovani found that combination of CXC motif chemokine ligand (CXCL) 1 and CXC motif chemokine receptor (CXCR) 2 participates in the malignant behavior of solid and hematological tumors, and these two ligands indirectly act on tumor angiogenesis by regulating the transport of leukocytes that produce angiogenic factors and a variety of inflammatory cytokines[30]. The CXCL1/CXCR2 signaling pathway can regulate inflammation, promote tumor cell proliferation, invasion and transvascular metastasis, and play an important role in the progression of inflammation[31]. In animal experiments, Thaker *et al*[32] found that IDO1 indoleamine 2,3 dioxygenase (IDO)-1 metabolites activate β-catenin signaling to promote the proliferation of mouse cancer cells and induce colitis-related tumors in mice, indicating that IDO1 may play an important role in the progression of colon cancer caused by UC. In addition, the lack of cell regulatory factors, especially anti-inflammatory factors, plays an increasingly important role in the pathogenesis of UC[33-35]. In a study of nearly 2000 subjects, Franke tested > 400000 single nucleotide polymorphisms through genome-wide association and found that interleukin-10 dysfunction is the core cause of UC[36]. With the gradual deepening of research, new susceptibility genes are constantly being discovered, but genetic studies can only explain 7.5% of the disease differences, and the correlation between UC genotype and clinical phenotype is not clear[28,37], indicating that the disease has obvious genetic heterogeneity and a complex genetic background.

**CONCLUSION**

Primary SRCC of the colorectum is extremely rare clinically. This type of colorectal cancer has certain clinical, pathological and biological characteristics that are different from ordinary colorectal cancer.

**REFERENCES**

1 **Kobayashi T**, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. *Nat Rev Dis Primers* 2020; **6**: 74 [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x]

2 **Farrokhyar F**, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. *Scand J Gastroenterol* 2001; **36**: 2-15 [PMID: 11218235 DOI: 10.1080/00365520150218002]

3 **Wang Y**, Ouyang Q; APDW 2004 Chinese IBD working group. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. *J Gastroenterol Hepatol* 2007; **22**: 1450-1455 [PMID: 17716349 DOI: 10.1111/j.1440-1746.2007.04873.x]

4 **Magro F**, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. *Inflamm Bowel Dis* 2012; **18**: 573-583 [PMID: 21793126 DOI: 10.1002/ibd.21815]

5 **Hugen N**, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. *Ann Oncol* 2014; **25**: 651-657 [PMID: 24504447 DOI: 10.1093/annonc/mdt591]

6 **Chew MH**, Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, Eu KW. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. *Int J Colorectal Dis* 2010; **25**: 1221-1229 [PMID: 20686777 DOI: 10.1007/s00384-010-1033-3]

7 **Song W**, Wu SJ, He YL, Cai SR, Zhang CH, Zhang XH, Zhan WH. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. *Chin Med J (Engl)* 2009; **122**: 1486-1491 [PMID: 19719934]

8 **Fahl JC**, Dockerty MB, Judd ES. Scirrhous carcinoma of the colon and rectum. *Surg Gynecol Obstet* 1960; **111**: 759-766 [PMID: 13697905]

9 **Amorn Y**, Knight WA Jr. Primary linitis plastica of the colon: report of two cases and review of the literature. *Cancer* 1978; **41**: 2420-2425 [PMID: 207410]

10 **Kang H**, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. *Dis Colon Rectum* 2005; **48**: 1161-1168 [PMID: 15868237 DOI: 10.1007/s10350-004-0932-1]

11 **Laufman H**, Saphir O. Primary linitis plastica type of carcinoma of the colon. *AMA Arch Surg* 1951; **62**: 79-91 [PMID: 14789350 DOI: 10.1001/archsurg.1951.01250030082009]

12 **Bonello JC**, Quan SH, Sternberg SS. Primary linitis plastica of the rectum. *Dis Colon Rectum* 1980; **23**: 337-42U [PMID: 6249557 DOI: 10.1007/bf02586841]

13 **Almagro UA**. Primary signet-ring carcinoma of the colon. *Cancer* 1983; **52**: 1453-1457 [PMID: 6311394 DOI: 10.1002/1097-0142(19831015)52:8<1453::aid-cncr2820520819>3.0.co;2-9]

14 **Desai SR**, Tata HR. Primary signet ring carcinoma of the large bowel--a case report. *Indian J Pathol Microbiol* 2004; **47**: 535-537 [PMID: 16295388]

15 **Bianchi G**, Terrinoni V, Lamazza A, Anselmi W, Abate O, Bellini N, Carbone G, Rengo M. [Signet ring cell adenocarcinoma of the colon (signet ring carcinoma): is it really a rare neoplasm?]. *G Chir* 1997; **18**: 283-285 [PMID: 9312256]

16 **Giacchero A**, Aste H, Baracchini P, Conio M, Fulcheri E, Lapertosa G, Tanzi R. Primary signet-ring carcinoma of the large bowel. Report of nine cases. *Cancer* 1985; **56**: 2723-2726 [PMID: 2996745 DOI: 10.1002/1097-0142(19851201)56:11<2723::aid-cncr2820561137>3.0.co;2-n]

17 **Pontes J**, Fernandes C, Panao E, Castro L, Vicente L, Neto M, Campos M, Pontes F. Synchronic signet ring carcinoma and adenocarcinoma complicating extensive and long-standing ulcerative colitis. *Hepatogastroenterology* 1999; **46**: 236-239 [PMID: 10228799]

18 **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]

19 **Itzkowitz SH**, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. *Gastroenterology* 2004; **126**: 1634-1648 [PMID: 15168373 DOI: 10.1053/j.gastro.2004.03.025]

20 **Vogelstein B**, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; **319**: 525-532 [PMID: 2841597 DOI: 10.1056/NEJM198809013190901]

21 **Nishida A**, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018; **11**: 1-10 [PMID: 29285689 DOI: 10.1007/s12328-017-0813-5]

22 **Hold GL**, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? *World J Gastroenterol* 2014; **20**: 1192-1210 [PMID: 24574795 DOI: 10.3748/wjg.v20.i5.1192]

23 **Huang LJ**, Mao XT, Li YY, Liu DD, Fan KQ, Liu RB, Wu TT, Wang HL, Zhang Y, Yang B, Ye CQ, Zhong JY, Chai RJ, Cao Q, Jin J. Multiomics analyses reveal a critical role of selenium in controlling T cell differentiation in Crohn's disease. *Immunity* 2021; **54**: 1728-1744 [PMID: 34343498 DOI: 10.1016/j.immuni.2021.07.004]

24 **Pedersen J**, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64]

25 **Halme L**, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. *World J Gastroenterol* 2006; **12**: 3668-3672 [PMID: 16773682 DOI: 10.3748/wjg.v12.i23.3668]

26 **Moller FT**, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. *Am J Gastroenterol* 2015; **110**: 564-571 [PMID: 25803400 DOI: 10.1038/ajg.2015.50]

27 **Liu JZ**, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Dayani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JY, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium, Barrett JC, Alizadeh BZ, Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. *Nat Genet* 2015; **47**: 979-986 [PMID: 26192919 DOI: 10.1038/ng.3359]

28 **Jostins L**, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012; **491**:119-124 [PMID: 23128233 DOI: 10.1038/nature11582]

29 **Chen ZA**, Sun YF, Wang QX, Ma HH, Ma ZZ, Yang CJ. Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis. *Front Genet* 2021; **12**: 697514 [PMID: 34306038 DOI: 10.3389/fgene.2021.697514]

30 **Mantovani A**, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. *Cytokine Growth Factor Rev* 2010; **21**: 27-39 [PMID: 20004131 DOI: 10.1016/j.cytogfr.2009.11.007]

31 **Acharyya S**, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J. A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell* 2012; **150**: 165-178 [PMID: 22770218 DOI: 10.1016/j.cell.2012.04.042]

32 **Thaker AI**, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, Newberry RD, Stenson WF, Ciorba MA. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. *Gastroenterology* 2013; **145**: 416-25 [PMID: 23669411 DOI: 10.1053/j.gastro.2013.05.002]

33 **Heller F**, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. *Immunity* 2002; **17**: 629-638 [PMID: 12433369 DOI: 10.1016/s1074-7613(02)00453-3]

34 **Sugimoto K**, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. *J Clin Invest* 2008; **118**: 534-544 [PMID: 18172556 DOI: 10.1172/JCI33194]

35 **Chen Y**, Chen Y, Cao P, Su W, Zhan N, Dong W. Fusobacterium nucleatum facilitates ulcerative colitis through activating IL-17F signaling to NF-κB *via* the upregulation of CARD3 expression. *J Pathol* 2020; **250**: 170-182 [PMID: 31610014 DOI: 10.1002/path.5358]

36 **Franke A**, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH; IBSEN study group, Mathew CG, Schreiber S. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. *Nat Genet* 2008; **40**: 1319-1323 [PMID: 18836448 DOI: 10.1038/ng.221]

37 **UK IBD Genetics Consortium**, Barrett JC, Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A, Wesley E, Parnell K, Zhang H, Drummond H, Nimmo ER, Massey D, Blaszczyk K, Elliott T, Cotterill L, Dallal H, Lobo AJ, Mowat C, Sanderson JD, Jewell DP, Newman WG, Edwards C, Ahmad T, Mansfield JC, Satsangi J, Parkes M, Mathew CG; Wellcome Trust Case Control Consortium 2, Donnelly P, Peltonen L, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Duncanson A, Jankowski J, Markus HS, Mathew CG, McCarthy MI, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Samani N, Trembath RC, Viswanathan AC, Wood N, Spencer CC, Barrett JC, Bellenguez C, Davison D, Freeman C, Strange A, Donnelly P, Langford C, Hunt SE, Edkins S, Gwilliam R, Blackburn H, Bumpstead SJ, Dronov S, Gillman M, Gray E, Hammond N, Jayakumar A, McCann OT, Liddle J, Perez ML, Potter SC, Ravindrarajah R, Ricketts M, Waller M, Weston P, Widaa S, Whittaker P, Deloukas P, Peltonen L, Mathew CG, Blackwell JM, Brown MA, Corvin A, McCarthy MI, Spencer CC, Attwood AP, Stephens J, Sambrook J, Ouwehand WH, McArdle WL, Ring SM, Strachan DP. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet* 2009; **41**: 1330-1334 [PMID: 19915572 DOI: 10.1038/ng.483]

**Footnotes**

**Informed consent statement:** The study participants and their legal guardian provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** We state that there is no financial or other relationship that might be perceived as leading to a conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 15, 2021

**First decision:** December 1, 2021

**Article in press:** December 28, 2021

**Specialty type:** Surgery

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Brochard C, Habeeb TAAM **S-Editor:** Wang JL **L-Editor:** Kerr C **P-Editor:** Wang JL

**Figure Legends**




**Figure 1 Preoperative colonoscopy.** The surface showed nodular or cauliflower-like changes; the rectal mucosa was congested and showed edema; the surface showed longitudinal changes, with many scattered small ulcers and a little mucus-like white coating on the surface or a small amount of bleeding. The intestinal cavity was so narrow that the endoscope was unable to pass.



**Figure 2 Preoperative computed tomography examination.** A: The rectal wall thickened uniformly in stages, and the intestinal cavity was obviously narrowed; B: The rectal mucosal layer was obviously strengthened (the area indicated by the white arrow, 2019/11/28).



**Figure 3 Gross specimen after surgery.** The excised intestine had a length of 67 cm and a diameter of 3.5-7.5 cm. The intestine was cut along the opposite side of the mesentery. There were multiple congestions with superficial ulcers on the mucosal surface of the intestinal canal, with a segmental distribution. The wall of the tube 1-16 cm from the rectal stump was diffusely thickened and stiff, with a wall thickness of about 1.2 cm, and the mucosae were polypoid and fused with each other.



**Figure 4 Postoperative pathological section.** A and B: Tumor cells infiltrated the tissue stroma. They were rich in cytoplasm and full of mucus, and the nucleus was squeezed on the side of the cytoplasm, resembling a signet ring (hematoxylin and eosin, 10 ×); C: Tumor cells invaded the colonic mucosa and submucosa, and the polarity of the glandular epithelial cells was still normal; D: Tumor cells invaded the entire thickness of the appendix; E: Ki-67 > 90% in the hotspot area; F: The tissue stroma of the upper rectum near the peritoneum reflex was filled with tumor cells, so an intestinal origin was considered in combination with morphology.

**Table 1 Mutations of gene detection results**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Mutant gene** | **Abundance (%)** | **Exon** | **cDNA** | **Protein** | **Type** |
| *MTOR* | 0.61 | 47 | c.6617A>G | p.N2206S | Non-synonymous |
| *HRAS* | 0.85 | 2 | c.81T>C | p.H27H | Synonymous |
| *SLCO1B1* | 0.79 | 6 | c.597C>T | p.F199F | Synonymous |
| *AKT1* | 0.57 | 3 | c.103T>C | p.F35L | Non-synonymous |
| *TP53* | 0.5 | 8 | c.840A>G | p.R280R | Synonymous |
| *STK11* | 0.51 | 4 | c.524A>T | p.K175M | Non-synonymous |
| 0.51 | 4 | c.530T>C | p.I177T | Non-synonymous |
| *XRCC1* | 0.66 | 10 | c.1196A>G | p.Q399R | Non-synonymous |
| *VHL* | 13.95 | 2 | c.T355C | p.F119L | Non-synonymous |
| *XRCC1* | 10.34 | 6 | c.C580T | p.R194W | Non-synonymous |

**Table 2 Mutations of gene detection results**

|  |  |
| --- | --- |
| **Gene** | **Mutation detection results** |
| *KRAS* | Wild |
| *NRAS* | Wild |
| *BRAF* | Wild |
| *NTRK* | Not detected |
| *BAT25* | Not detected |
| *BAT26* | Not detected |
| *NR21* | Not detected |
| *NR24* | Not detected |
| *NR27* | Not detected |

徽标, 公司名称

描述已自动生成

Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com

QR 代码

描述已自动生成

**© 2022 Baishideng Publishing Group Inc. All rights reserved.**